ME1 50.0% 0.1¢ melodiol global health limited

ME1 Investor Stream Interview

  1. 245 Posts.
    lightbulb Created with Sketch. 54

    Interesting interview - pretty overarching view of the Q3 revenue growth and sounds like it's sustainable.

    Good update on Halucnex too - if the clinical trials continue on this trajectory it could be a gamechanger.

    But the big takeaway was the question relating revenue growth to share price. Surely this level of sustained revenue growth translates into some uplift in the SP?
 
watchlist Created with Sketch. Add ME1 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.